Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides metabolic energy via glycolysis and the Krebs cycle, replenishing extracellular fluid glucose. Sodium and chloride are major extracellular electrolytes that maintain osmotic pressure and fluid balance; chloride serves as a counterion for acid-base regulation. Potassium is the primary intracellular cation essential for membrane potential, nerve impulse transmission, and muscle contraction. The solution provides water, electrolytes, and calories to correct fluid, electrolyte, and caloric deficits.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement in patients with mild to moderate hyponatremia and hypokalemia,Maintenance of hydration and provision of calories to prevent ketosis in patients unable to take oral fluids,Replacement of water, sodium, chloride, and potassium losses in isotonic or hypotonic dehydration
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; dose depends on fluid, electrolyte, and caloric needs. Typical adult dose: 1000-2000 m L/day, administered at 100-200 m L/hour. Potassium replacement: 20 m Eq/L of solution, infused at a rate not exceeding 10 m Eq/hour, with a maximum daily dose of 200 m Eq.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Glucose: 1.5-2 h; potassium: 8-12 h; sodium: 12-24 h; clinical context: half-life affected by renal function and total body stores.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized in all tissues via glycolysis to pyruvate, then enters the Krebs cycle; excess is stored as glycogen or converted to fat. Sodium and chloride are not metabolized but excreted renally under hormonal control (aldosterone, ADH). Potassium is actively transported into cells via Na+/K+-ATPase and excreted primarily by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: glucose <0.5% excreted unchanged; sodium and potassium >90% reabsorbed; chloride follows sodium. Biliary/fecal: negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Glucose: none; sodium and chloride: none; potassium: none.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Glucose: 0.2-0.3 L/kg (extracellular fluid); sodium: 0.15-0.2 L/kg (plasma and interstitial); potassium: 0.4-0.6 L/kg (total body water).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% for all components; oral: not applicable (IV only).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR >50 m L/min: No adjustment. GFR 10-50 m L/min: Reduce infusion rate; monitor serum potassium; avoid if hyperkalemia risk. GFR <10 m L/min: Use with extreme caution; consider alternative potassium source; monitor ECG and serum potassium frequently.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: No specific adjustment. Class B: Reduced doses due to potential for fluid retention; monitor serum potassium. Class C: Avoid due to increased risk of hyperkalemia and fluid overload.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion; dose based on weight and clinical status. Typical: 5-10 m L/kg/day of the solution, adjusted for electrolyte needs. Infusion rate: Do not exceed 0.5 m Eq/kg/hour of potassium. Maximum potassium concentration: 40 m Eq/L. Monitor serum electrolytes closely.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients may have decreased renal function; initiate at lower infusion rates (e.g., 50-100 m L/hour) and titrate based on serum potassium. Monitor renal function and electrolytes frequently; avoid overhydration.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Monitor serum electrolytes, fluid balance, and renal function. Use with caution in patients with cardiac or renal impairment, hyperkalemia, hyponatremia, or conditions predisposing to fluid overload (heart failure, pulmonary edema). Rapid infusion may cause hyperglycemia, hyperosmolarity, or osmotic diuresis. Potassium-containing solutions must be administered with care in patients on potassium-sparing diuretics, ACE inhibitors, or with impaired renal function. Do not administer unless solution is clear and container undamaged.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia, severe renal insufficiency (oliguria or anuria), hypernatremia, fluid overload states (e.g., pulmonary edema, decompensated heart failure), severe hypokalemia (until corrected), and known hypersensitivity to any component.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, potassium intake from diet should be considered in patients with renal impairment or hyperkalemia. Avoid salt substitutes containing potassium without medical advice.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
FDA Pregnancy Category C. Dextrose and electrolytes are generally considered low risk when used at physiological doses. Potassium chloride is essential for fetal development; hyperkalemia or hypokalemia may cause fetal arrhythmias. No known teratogenicity in first trimester. Second and third trimester: risk of electrolyte imbalances affecting fetal homeostasis. Use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Compatible with breastfeeding. Dextrose and electrolytes are normal constituents of human milk. Potassium levels in milk are tightly regulated; M/P ratio not applicable. No adverse effects reported.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy increases plasma volume and GFR, which may alter electrolyte requirements. Dose adjustments are generally not needed for maintenance; however, consider increased fluid and electrolyte needs. Monitor potassium levels closely as total body potassium changes. Adjust infusion rate based on maternal electrolyte status.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Do not administer if solution is discolored or contains precipitate. Inspect for leaks and ensure container is intact. Use strict aseptic technique when spiking bag. Monitor serum potassium levels closely in renal impairment. Rate of infusion should not exceed 0.5-1 m Eq/kg/hour potassium. Do not add other medications unless compatibility verified. For peripheral administration, ensure proper vein selection to avoid phlebitis.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any pain, redness, or swelling at the IV site immediately.,Inform your doctor if you have kidney problems, heart disease, or are on a low-potassium diet.,This solution contains dextrose; if you are diabetic, your blood sugar will be monitored.,Do not adjust the IV drip rate yourself.,Tell your doctor if you experience muscle weakness, tingling, or irregular heartbeat.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is a Electrolyte that works by Dextrose is a monosaccharide that provides metabolic energy via glycolysis and the Krebs cycle, replenishing extracellular fluid glucose. Sodium and chloride are major extracellular electrolytes that maintain osmotic pressure and fluid balance; chloride serves as a counterion for acid-base regulation. Potassium is the primary intracellular cation essential for membrane potential, nerve impulse transmission, and muscle contraction. The solution provides water, electrolytes, and calories to correct fluid, electrolyte, and caloric deficits.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is: Intravenous infusion; dose depends on fluid, electrolyte, and caloric needs. Typical adult dose: 1000-2000 m L/day, administered at 100-200 m L/hour. Potassium replacement: 20 m Eq/L of solution, infused at a rate not exceeding 10 m Eq/hour, with a maximum daily dose of 200 m Eq.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is classified as Category A/B. FDA Pregnancy Category C. Dextrose and electrolytes are generally considered low risk when used at physiological doses. Potassium chloride is essential for fetal development; hyper. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.